Prolactinomas: diagnosis and treatment
- 1 March 2012
- journal article
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 7 (2) , 233-241
Abstract
Pituitary lactotrophs secrete prolactin. This process is enhanced by estrogen and inhibited by dopamine. Prolactinomas are benign neoplasms that rarely increase in size and are classified according to size as microadenomas (10 mm diameter). The clinical features of prolactinomas most commonly result from prolactin's effect on the gonads and breast in women and from mass effect in men. This review details the clinical features and management of patients with prolactinomas.Keywords
This publication has 68 references indexed in Scilit:
- Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias?Clinical Endocrinology, 2011
- Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapyEuropean Journal of Endocrinology, 2009
- Gamma Knife Radiosurgery for Medically and Surgically Refractory ProlactinomasNeurosurgery, 2006
- Medication-Induced HyperprolactinemiaMayo Clinic Proceedings, 2005
- Long‐term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomasClinical Endocrinology, 2005
- Alteration of Gα Subunits mRNA Levels in Bromocriptine Resistant ProlactinomasJournal of Neuroendocrinology, 1996
- Pregnancy outcome after treatment with the ergot derivative, cabergolineReproductive Toxicology, 1996
- Bromocriptine in pregnancy: Safety aspectsJournal of Molecular Medicine, 1987
- Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumorsJournal of Neurosurgery, 1984
- Prolactin-Secreting Tumors and Hypogonadism in 22 MenNew England Journal of Medicine, 1978